Clinical trial
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
NCT02912455
Study timeline
Study start (actual)2017-01-05Date precision: day
Registry last updated2020-11-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 2unresolved
Obesityunresolved
Interventions
canagliflozinDRUG · verified · RxNorm: canagliflozin
Sponsors & collaborators
The Cleveland Cliniclead sponsor
Janssen Scientific Affairs, LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02912455 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.